Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance

Molecularly targeted therapies, directed against the features of a given tumor, have allowed for a personalized approach to the treatment of advanced non-small-cell lung cancer (NSCLC). The reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib h...

Descripción completa

Detalles Bibliográficos
Autores principales: Jotte, Robert M, Spigel, David R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673988/
https://www.ncbi.nlm.nih.gov/pubmed/26310719
http://dx.doi.org/10.1002/cam4.506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673988/
https://www.ncbi.nlm.nih.gov/pubmed/26310719
http://dx.doi.org/10.1002/cam4.506

Ejemplares similares